Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental REMS (Risk Evaluation and Mitigation Strategy) for mycophenolate mofetil oral suspension 200 mg/mL marketed by Teva Pharmaceuticals USA, effective 29 July 2026. This is a regulatory action governing safe distribution and use; the record contains no clinical trial results, efficacy data, or comparative evidence.

What was studied

Regulatory label update.

Key findings

Supplemental REMS approval for mycophenolate mofetil oral suspension formulation (200 mg/mL)

Safety

This record does not contain clinical trial results, efficacy data, safety outcomes, or comparative benefits.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval of a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; this is a regulatory action, not a clinical trial, and does not report efficacy or comparative clinical outcomes.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-07-29

Formulation strength200 mg/mL

Caveats

This record does not contain clinical trial results, efficacy data, safety outcomes, or comparative benefits.
REMS approval relates to risk management and distribution controls, not clinical efficacy or superiority.
No patient population, sample size, or outcome metrics are reported.
The specific REMS requirements and clinical rationale are not detailed in this regulatory record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

This is a regulatory action, not a clinical study; no study design applies.

Directness

insufficient

Regulatory record does not report clinical trial data or direct patient outcomes.

Consistency

insufficient

No comparative clinical data provided in this regulatory document.

Risk of bias

insufficient

Risk of bias assessment not applicable to regulatory approval records.

Sample adequacy

insufficient

No clinical trial or patient sample described in this regulatory action.

Source abstract

Drugs@FDA record for application ANDA211272. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: TEVA PHARMS USA. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, FOR SUSPENSION, ORAL, MYCOPHENOLATE MOFETIL 200MG/ML.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilTeva Pharms U